REVVITY, INC. (RVTY) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 30, 2025. Revvity, Inc. is a leading provider of health science solutions, technologies, and services. Effective at the beginning of fiscal year 2025, the Company reorganized its operating model. The Life Sciences segment now includes Life Sciences Solutions and Software, while the Diagnostics segment consists of Immunodiagnostics and Reproductive Health. The Company is a large accelerated filer incorporated in Massachusetts.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $664,762 | $649,920 |
| Operating Income | $72,230 | $44,116 |
| Net Income | $42,237 | $26,013 |
| Diluted EPS | $0.35 | $0.21 |
| Operating Cash Flow | $128,155 | $147,563 |
| Cash and Equivalents | $1,137,620 | $998,081 |
| Total Debt (Carrying Value) | $3,168,626 | $3,150,718 |
| Gross Margin | 56.5% | 54.6% |
| Operating Margin | 10.9% | 6.8% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 2% ($14.8 million) year-over-year. The Diagnostics segment drove growth with a 3% increase ($11.0 million), while Life Sciences grew 1% ($3.9 million).
- Profitability Expansion: Operating income surged 64% to $72.2 million, driven by gross margin expansion (up 186 basis points) and cost containment. Operating margin improved from 7% to 11%.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased 4% ($10.9 million) despite a $10.6 million charge for significant litigation matters. Restructuring costs dropped significantly from $12.4 million to $3.2 million.
- Discontinued Operations: The Company recorded a $0.6 million gain from discontinued operations in Q1 2025, compared to a $2.7 million loss in Q1 2024, related to the sale of its Applied, Food, and Enterprise Services businesses.
- Shareholder Returns: The Company repurchased $153.6 million of common stock in Q1 2025, a significant increase from $10.8 million in the prior year period. A quarterly dividend of $0.07 per share was declared.
Guidance, Outlook, and Risks
- Tariff Impact: Management estimates that recently enacted tariffs could increase gross cost of revenue by approximately $135 million for the fiscal year. However, through mitigation strategies (pricing, operational adjustments), the expected impact on operating income is reduced to approximately $20 million.
- Tax Outlook: The effective tax rate for Q1 2025 was 20.5%. Management expects the effective tax rate for fiscal year 2025 to be approximately 20% before discrete items.
- Liquidity: The Company maintains $1.5 billion in borrowing capacity under a new senior unsecured revolving credit facility (renewed Jan 2025, maturing 2030). $707.2 million remains available under the $1.0 billion share repurchase program.
- Risks: Key risks include global economic conditions, government funding uncertainties for customers, supply chain disruptions, and potential impairment of significant intangible assets ($9.1 billion net carrying value).
Investor Verification Checklist
- Tariff Mitigation: Verify the progress of operational adjustments and pricing actions intended to neutralize the estimated $135 million tariff impact on costs.
- Intangible Assets: Review the valuation assumptions for the $9.1 billion in net intangible assets, particularly given the high amortization expense ($82.7 million in Q1).
- Segment Mix: Monitor the shift in revenue mix between the Life Sciences Solutions (down $5.2M) and Software (up $9.0M) lines within the Life Sciences segment.
- Legal Contingencies: Assess the status of the "significant litigation matters" that incurred a $10.6 million expense in Q1 2025.
- Debt Covenants: Confirm compliance with financial covenants, specifically the debt-to-capitalization ratio, under the new 2025 credit facility.